Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
Brian Dougherty(AstraZeneca (United States)), J. Carl Barrett(National Institute of Environmental Health Sciences), Tony W. Ho(Johns Hopkins University), Anitra Fielding(AstraZeneca (United States)), Matthew Hawryluk(Foundation Medicine (United States)), Jonathan A. Ledermann(London Cancer), Roman Yelensky(National Vaccine and Serum Institute), Darren Hodgson(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Stuart Spencer(AstraZeneca (United Kingdom)), Zhongwu Lai(AstraZeneca (United States)), Maria Orr(AstraZeneca (United Kingdom)), James Sun(GlobalFoundries (United States))
Cited by 99
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k